Prostate Cancer Coverage from Every Angle

Michael J. Morris, MD, on the Alliance Trial: Clinical Implications of Combination Therapy for Prostate Cancer

Posted: Monday, June 24, 2019

Michael J. Morris, MD, of Memorial Sloan Kettering Cancer Center, discusses whether the combination of abiraterone acetate and enzalutamide will play a role in the future treatment of metastatic castration-resistant prostate cancer.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.